Navigation Links
MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Date:3/13/2008

--------------------------------------------

Unattributed Expenses

Personnel $0.7 $0.7 $2.2 $2.0

Patent costs 0.1 0.2 0.7 0.6

Other 0.2 0.2 0.8 0.8

--------------------------------------------

Total Unattributed Expenses $1.0 $1.1 $3.7 $3.4

--------------------------------------------

Total Research & Development

Expenses $1.5 $2.1 $5.0 $5.6

--------------------------------------------

--------------------------------------------

(1) Before amortization expense, technology and license acquisition

costs, and write-downs of intangibles assets.

(2) Value of $0.0 million represents $nil to ~$50,000 in expenses during

the period.

Our Omiganan programs are being advanced by development and commercialization partners (Cadence Pharmaceuticals and Cutanea Life Sciences).

Celgosivir program costs were $0.3 million in Q3/08 (Q3/07: $0.4 million) and were $1.0 million for YTD Fiscal 2008 (YTD Fiscal 2007: $1.1 million).

Costs in the MX-2401 program in Q3/08 were $0.1 million (Q3/07: $0.4 million) and were $0.2 million for YTD Fiscal 2008 (YTD Fiscal 2007: $1.0 million). The decrease in Q3/08 and YTD Fiscal 2008 MX-2401 costs is principally due to higher cost manufacturing activity in Q3/07 and YTD Fiscal 2007 in preparation for the GLP studies started in April 2007.

Research and development costs not allocated to programs were $1.0 million in Q3/08 (Q3/07: $1.1 million) and were $3.7 million for YTD Fiscal 2008 (YTD Fiscal 2007: $3.4 million). The approximate $0.3 million increase in these unallocated research and development
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX releases CEO message #22
3. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
4. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
8. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
9. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... July 21, 2015 ... the addition of the "Analysis of the ... their offering. Globally, flow cytometry remains ... cell proliferation, cancer, and stem cells. But the ... primarily because of demand from underdeveloped nations to ...
(Date:7/28/2015)... ... ... VetStem Biopharma will be offering weekly private guided tours of our new ... The tour and course will be given every Wednesday at 6pm to local interested ... members are welcome to attend with their veterinarian as well. Participants will be able ...
(Date:7/28/2015)... , July 28, 2015 Tauriga Sciences, Inc. ... life sciences company, today announced that its stockholders approved ... common stock of the Company from 1,000,000,000 to 2,500,000,000 ... 27, 2015 at the Law Offices of Nixon Peabody ... Special Meeting, there were 480,655,929 shares of common stock ...
(Date:7/28/2015)... N.J. , July 28, 2015  Moerae ... second Phase 1 clinical trial with MMI-0100, a ... is being developed for pulmonary disorders characterized by ... United Kingdom , is a ... further evaluating the safety and tolerability of MMI-0100 ...
Breaking Biology Technology:Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2
... pioneer,William J. Rutter, PhD, will deliver a keynote ... in San Francisco next month, the,Regulatory Affairs Professionals ... CEO of Synergenics LLC and co-founder of biotech,industry ... on,the regulatory implications of advances in biological and ...
... public policy with the needs of consumers and the ... of reducing the effects of carbon on the climate, ... American Association for the Advancement of Science (AAAS). ... energy system, says Mike Davis, who leads the Energy ...
... 15 VION,PHARMACEUTICALS, INC. (Nasdaq: VION ) today ... 2008 on its 7.75% Convertible Senior Notes,due 2012 (the ... $60,million., The Company paid $2,376,666.67 through the issuance ... paid in 5,500,800,shares of Common Stock, based on today,s ...
Cached Biology Technology:Biotech Pioneer William J. Rutter to Deliver Keynote at 2008 RAPS Horizons Conference 2Mission critical for carbon management 2Mission critical for carbon management 3Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes 2
(Date:7/21/2015)... YORK , July 21, 2015 ... systems, as seen in the recent U.S. Office ... a solution to the infosec conundrum, but developers ... is stored. To address this dilemma, Biometrics-as-a-Service provider ... its Biometric Tokenization SDK for third party integration. ...
(Date:7/13/2015)... JOSE, Calif. , July 13, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... generation touch and display driver integration (TDDI) product ... is the first to combine Synaptics , ... with proven display driver technology developed in the ...
(Date:7/9/2015)...  Synaptics Inc. (NASDAQ: SYNA ), a leading developer ... report financial results for the fourth quarter and fiscal ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-455-2260 (conference ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... Researchers have experimentally shown that some species of reef ... that stealthily attack them from behind and take a ... The study, published online on November 4 in ... punishment ultimately serves all members of the reef fish ...
... R.I. [Brown University] Drop that doughnut. In a ... $3.4 million grant from the National Cancer Institute, health ... a low-priced, fresh produce market within workplaces will motivate ... been no other studies like this," said Kim Gans, ...
... critical processes within the body, including muscle contraction, the ... calcium can be a bad thing. In excess, it ... severe muscle weakness, a fatal reaction to anesthesia or ... the Stanford Synchrotron Radiation Lightsource (SSRL) at the Department ...
Cached Biology News:To punish or not to punish: Lessons from reef fish and saber-tooth blennies 2To punish or not to punish: Lessons from reef fish and saber-tooth blennies 3Would convenient access to affordable fresh produce improve eating habits? 2Would convenient access to affordable fresh produce improve eating habits? 3X-rays offer first detailed look at hotspots for calcium-related disease 2
Mouse monoclonal antibody raised against a full length recombinant LDB3. NCBI Entrez Gene ID = LDB3...
...
Mouse monoclonal antibody to UGT2B10 - UDP glucuronosyltransferase 2 family, polypeptide B10...
Mouse polyclonal antibody raised against a partial recombinant COASY. NCBI Entrez Gene ID = 80347...
Biology Products: